Literature DB >> 18021472

Liver involvement in multiple myeloma.

Meghana S Bhandari1, Amitabha Mazumder, David H Vesole.   

Abstract

Clinical manifestations of liver involvement in multiple myeloma (MM) are uncommon. Rare cases of MM present as acute liver disease. We report a case of a 55-year-old woman with MM who presented with painless jaundice, mild pruritus, and abnormal liver function tests resembling acute cholestatic hepatitis without the stigmata of chronic liver disease. Initial laboratories included elevated liver function tests (aspartate aminotransferase 74 U/L and alanine aminotransferase 45 U/L) and an elevated white blood cell count of 19,600 cells/microL with 33% circulating plasma cells. Myeloma parameters demonstrated an immunoglobulin G lambda monoclonal protein with lambda light-chain Bence-Jones proteinuria. Bone marrow was hypercellular with 70% plasmacytosis. A liver biopsy revealed a diffuse portal and sinusoidal infiltration of plasma cells with lambda light-chain restriction. In this report, we review the literature of liver involvement in MM.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18021472     DOI: 10.3816/clm.2007.n.039

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma        ISSN: 1557-9190


  10 in total

1.  Amyloidosis and subacute liver failure.

Authors:  Moby Joseph; Timothy J S Cross
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-03

2.  Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.

Authors:  Patricia M LoRusso; Karthik Venkatakrishnan; Ramesh K Ramanathan; John Sarantopoulos; Daniel Mulkerin; Stephen I Shibata; Anne Hamilton; Afshin Dowlati; Sridhar Mani; Michelle A Rudek; Chris H Takimoto; Rachel Neuwirth; Dixie-Lee Esseltine; Percy Ivy
Journal:  Clin Cancer Res       Date:  2012-03-06       Impact factor: 12.531

Review 3.  Does my patient with a serum monoclonal spike have multiple myeloma?

Authors:  Giada Bianchi; Irene M Ghobrial
Journal:  Hematol Oncol Clin North Am       Date:  2012-04       Impact factor: 3.722

Review 4.  The use of novel agents in multiple myeloma patients with hepatic impairment.

Authors:  Lindsay C Stansfield; Wilson I Gonsalves; Francis K Buadi
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

5.  Concurrent presentation of hodgkin lymphoma and multiple myeloma.

Authors:  Rekha Chandran; Miklos Simon; Stephen E Spurgeon
Journal:  Case Rep Hematol       Date:  2013-08-20

6.  Living donor liver transplantation prior to multiple myeloma treatment in a patient with hepatitis B-associated hepatocellular carcinoma and liver cirrhosis: a case report.

Authors:  Chan Woo Cho; Nuri Lee; Gyu-Seong Choi; Jong Man Kim; Choon Hyuck David Kwon; Jae-Won Joh
Journal:  Ann Surg Treat Res       Date:  2018-03-26       Impact factor: 1.859

Review 7.  Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor.

Authors:  Neeraj Gupta; Michael J Hanley; Cindy Xia; Richard Labotka; R Donald Harvey; Karthik Venkatakrishnan
Journal:  Clin Pharmacokinet       Date:  2019-04       Impact factor: 6.447

8.  Management of Multiple Myeloma Complicated by Hepatitis C Virus Reactivation: The Role of New Antiviral Therapy.

Authors:  Parag Mahale; Sheeba K Thomas; Andreas Kyvernitakis; Harrys A Torres
Journal:  Open Forum Infect Dis       Date:  2015-12-28       Impact factor: 3.835

9.  Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study.

Authors:  Jennifer Brown; Ruth Plummer; Todd M Bauer; Stephen Anthony; John Sarantopoulos; Filip De Vos; Mike White; Marco Schupp; Ying Ou; Ulka Vaishampayan
Journal:  Exp Hematol Oncol       Date:  2017-10-03

10.  Proposal for a Quantitative 18F-FDG PET/CT Metabolic Parameter to Assess the Intensity of Bone Involvement in Multiple Myeloma.

Authors:  Maria E S Takahashi; Camila Mosci; Edna M Souza; Sérgio Q Brunetto; Elba Etchebehere; Allan O Santos; Mariana R Camacho; Eliana Miranda; Mariana C L Lima; Barbara J Amorim; Carmino de Souza; Fernando V Pericole; Irene Lorand-Metze; Celso D Ramos
Journal:  Sci Rep       Date:  2019-11-11       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.